Published in Biochem Biophys Res Commun on May 17, 2002
Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci (2008) 2.09
Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule. Proc Natl Acad Sci U S A (2004) 1.53
Dynamic Network Connectivity: A new form of neuroplasticity. Trends Cogn Sci (2010) 1.48
"Nanosized voltmeter" enables cellular-wide electric field mapping. Biophys J (2007) 1.37
Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice. PLoS One (2011) 1.15
Phospholipase A2 and arachidonic acid in Alzheimer's disease. Biochim Biophys Acta (2010) 1.07
Effect of sterols on beta-amyloid peptide (AbetaP 1-40) channel formation and their properties in planar lipid membranes. Biophys J (2004) 1.04
Action mechanisms of transcranial direct current stimulation in Alzheimer's disease and memory loss. Front Psychiatry (2012) 0.95
Bexarotene reduces network excitability in models of Alzheimer's disease and epilepsy. Neurobiol Aging (2014) 0.93
Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5--implications for dementia with Lewy bodies. Mol Neurodegener (2014) 0.82
Ammonium hydroxide treatment of Aβ produces an aggregate free solution suitable for biophysical and cell culture characterization. PeerJ (2013) 0.81
Amyloid-β induces synaptic dysfunction through G protein-gated inwardly rectifying potassium channels in the fimbria-CA3 hippocampal synapse. Front Cell Neurosci (2013) 0.80
The role of beta-amyloid protein in synaptic function: implications for Alzheimer's disease therapy. Curr Neuropharmacol (2006) 0.80
Altered intrinsic excitability of hippocampal CA1 pyramidal neurons in aged PDAPP mice. Front Cell Neurosci (2015) 0.76
The Anti-Prion Antibody 15B3 Detects Toxic Amyloid-β Oligomers. J Alzheimers Dis (2016) 0.75
Exploring the mechanism of beta-amyloid toxicity attenuation by multivalent sialic acid polymers through the use of mathematical models. J Theor Biol (2009) 0.75
Impacts of membrane biophysics in Alzheimer's disease: from amyloid precursor protein processing to aβ Peptide-induced membrane changes. Int J Alzheimers Dis (2011) 0.75
Stochastic kinetics of intracellular huntingtin aggregate formation. Nat Chem Biol (2006) 1.81
Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule. Proc Natl Acad Sci U S A (2004) 1.53
Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display. J Mol Biol (2004) 1.10
Direct and selective elimination of specific prions and amyloids by 4,5-dianilinophthalimide and analogs. Proc Natl Acad Sci U S A (2008) 1.06
Genetic and structural characterization of an L201P global suppressor substitution in TEM-1 beta-lactamase. J Mol Biol (2008) 1.05
Atomic force microscopy analysis of the Huntington protein nanofibril formation. Nanomedicine (2005) 0.91
Eliminating membrane depolarization caused by the Alzheimer peptide Abeta(1-42, aggr.). Biochem Biophys Res Commun (2002) 0.89
Atomic force microscopy analysis of the Huntington protein nanofibril formation. Dis Mon (2005) 0.80
Ca(2+), within the physiological concentrations, selectively accelerates Abeta42 fibril formation and not Abeta40 in vitro. Biochim Biophys Acta (2009) 0.78